21.5mg per dose, 4 doses cartridge
Please recognize the extreme use of this product and that there can be extreme side effects if you do not tolerate the individual elements of Tirzpepatide and Eloralintide well. Use this drug and dosage only if you have problems losing appetite with individual elements or MaxFrari only.
Top of the line maximum appetite and urge suppressant drug is the combination of Tirzepatide and Eloralintide to offer the following benefits:
Combined Triple Effect
- Acting through complementary appetite and metabolic pathways rather than simply increasing stimulation of the same receptor by products such as MaxFrari or larger doses of Tirzepatide or Retatrutide.
- Tirzepatide activates the GIP and GLP-1 receptors, improving glucose regulation while reducing hunger and food intake. Eloralintide is a selective amylin-receptor agonist; amylin is another naturally occurring satiety hormone released after eating. Combining them therefore creates a triple-pathway approach—GIP + GLP-1 + amylin—that may produce stronger and potentially more sustained appetite suppression than tirzepatide and or retatrutide alone (AKA MaxFrari).
